There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.
Keaton Gaffney, PharmD, BCPS, BCOP
Advertisement
Articles by Keaton Gaffney, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5